Herbal Nephroprotective Agents Against Gentamicin-Induced Nephrotoxicity: Mechanisms, Experimental Evidence and Future Perspectives

The kidneys play a fundamental role in maintaining physiological homeostasis by regulating fluid and electrolyte balance, eliminating metabolic waste products, controlling blood pressure, maintaining acid-base equilibrium, and producing hormones essential for erythropoiesis and bone metabolism. Owing to their exceptionally high blood flow and their ability to concentrate endogenous and exogenous substances, the kidneys are particularly vulnerable to toxic insults caused by therapeutic agents, environmental chemicals, and metabolic by-products. Drug-induced nephrotoxicity has emerged as one of the most significant adverse effects associated with modern pharmacotherapy, accounting for a substantial proportion of acute kidney injury (AKI) cases reported in hospitalized patients [1]. Despite remarkable advances in drug development and patient monitoring, nephrotoxic medications continue to present major clinical challenges because they often compromise renal function, prolong hospital stays, increase healthcare costs, and elevate patient morbidity and mortality. Among these nephrotoxic agents, aminoglycoside antibiotics, particularly gentamicin, remain indispensable in the treatment of severe bacterial infections despite their well-recognized nephrotoxic potential [2].

Gentamicin has maintained an important position in clinical practice for several decades owing to its potent bactericidal activity against a wide range of Gram-negative pathogens, favorable pharmacokinetic profile, rapid onset of action, and relatively low cost. It is frequently prescribed for life-threatening infections including septicemia, urinary tract infections, intra-abdominal infections, respiratory tract infections, neonatal sepsis, infective endocarditis, and complicated hospital-acquired infections. Nevertheless, the therapeutic benefits of gentamicin are substantially limited by its dose-dependent nephrotoxicity, which develops in a considerable proportion of patients receiving prolonged therapy or high cumulative doses. Experimental investigations have demonstrated that gentamicin preferentially accumulates within the renal proximal tubular epithelial cells, initiating a cascade of oxidative stress, mitochondrial dysfunction, inflammatory responses, apoptosis, and structural degeneration that ultimately impair renal function. Consequently, understanding the molecular basis of gentamicin-induced nephrotoxicity and identifying effective nephroprotective interventions have become priorities in nephrology, pharmacology, and pharmaceutical research [3].

In recent years, increasing attention has been directed toward medicinal plants and naturally occurring phytochemicals as promising therapeutic strategies for mitigating drug-induced renal injury. Herbal medicines contain diverse classes of bioactive constituents, including flavonoids, polyphenols, alkaloids, terpenoids, saponins, tannins, glycosides, and polysaccharides, many of which possess potent antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective properties. Numerous experimental studies have reported that herbal extracts and isolated phytochemicals can attenuate gentamicin-induced renal damage by scavenging reactive oxygen species, restoring endogenous antioxidant defense systems, suppressing inflammatory mediators, preserving mitochondrial integrity, modulating intracellular signaling pathways, and improving renal histopathology. These findings have generated considerable interest in exploring herbal nephroprotective agents as complementary or adjunctive therapies capable of reducing renal toxicity without compromising the antibacterial efficacy of gentamicin [4].

The present review aims to comprehensively summarize current knowledge regarding herbal nephroprotective agents against gentamicin-induced nephrotoxicity by integrating evidence from experimental pharmacology, molecular biology, toxicology, and phytomedicine. Particular emphasis is placed on elucidating the mechanisms responsible for gentamicin-mediated renal injury, critically evaluating the nephroprotective efficacy of medicinal plants and their bioactive constituents, discussing the molecular pathways underlying their protective actions, and highlighting future opportunities for translational research. By consolidating existing evidence, this review seeks to provide researchers, clinicians, pharmacologists, and pharmaceutical scientists with an updated understanding of herbal nephroprotection and to facilitate the development of safer and more effective therapeutic approaches for preventing aminoglycoside-associated renal toxicity [5].

1. 1.  Burden of Drug-Induced Nephrotoxicity

Drug-induced nephrotoxicity represents one of the most common and clinically significant adverse drug reactions encountered in medical practice. The kidneys receive approximately 20–25% of the cardiac output despite constituting less than 1% of total body weight, exposing renal tissues to exceptionally high concentrations of circulating drugs, metabolites, and xenobiotics. In addition to their extensive blood supply, the kidneys actively concentrate many substances through glomerular filtration, tubular secretion, and tubular reabsorption, thereby increasing the exposure of renal tubular epithelial cells to potentially toxic compounds. These unique physiological characteristics make the kidneys particularly susceptible to structural and functional damage following exposure to nephrotoxic medications [6].

The growing prevalence of chronic diseases, expanding use of polypharmacy, increasing life expectancy, and widespread administration of potent antimicrobial, anticancer, immunosuppressive, and analgesic agents have collectively contributed to the rising incidence of drug-induced kidney injury worldwide. Elderly individuals, critically ill patients, individuals with diabetes mellitus or hypertension, patients with pre-existing renal impairment, and those receiving multiple nephrotoxic medications simultaneously represent particularly vulnerable populations. In these patients, even modest declines in renal function may significantly increase hospitalization rates, healthcare expenditures, and the risk of progression toward chronic kidney disease or end-stage renal disease [7].

Drug-induced nephrotoxicity encompasses a broad spectrum of pathological manifestations, including acute tubular necrosis, acute interstitial nephritis, glomerular injury, crystal nephropathy, thrombotic microangiopathy, osmotic nephrosis, and chronic tubulointerstitial fibrosis. The severity of renal damage depends on multiple factors, including drug dosage, duration of therapy, patient age, hydration status, genetic susceptibility, concurrent diseases, and interactions with other medications. Clinically, affected patients may present with elevated serum creatinine, increased blood urea nitrogen, reduced glomerular filtration rate, electrolyte disturbances, oliguria, proteinuria, or complete acute kidney injury requiring renal replacement therapy [8].

From a mechanistic perspective, drug-induced nephrotoxicity is mediated through multiple overlapping pathways involving oxidative stress, mitochondrial dysfunction, inflammatory activation, endothelial injury, impaired microcirculation, DNA damage, lysosomal disruption, and programmed cell death. These complex mechanisms have stimulated extensive research aimed at identifying pharmacological and non-pharmacological interventions capable of preserving renal function during drug therapy. Consequently, the search for safe, effective, and affordable nephroprotective agents has become an important area of biomedical investigation [9].

The socioeconomic consequences of drug-induced nephrotoxicity extend beyond individual patient outcomes. Hospital admissions related to acute kidney injury impose a substantial financial burden on healthcare systems worldwide because affected patients often require prolonged hospitalization, intensive monitoring, dialysis support, and long-term follow-up. Preventing nephrotoxicity therefore represents not only an important clinical objective but also a significant public health priority. This has encouraged the exploration of innovative nephroprotective strategies, including the use of naturally derived therapeutic agents with multitarget pharmacological properties [10].

1. 2.  Clinical Applications of Gentamicin

Gentamicin is a broad-spectrum aminoglycoside antibiotic that has remained an essential component of antimicrobial therapy for more than five decades. Originally introduced because of its potent activity against aerobic Gram-negative bacteria, gentamicin continues to play a vital role in the management of serious infections caused by organisms such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus species, Enterobacter species, and Serratia species. In addition, gentamicin is frequently administered in combination with β-lactam antibiotics or glycopeptides to achieve synergistic antibacterial activity against selected Gram-positive organisms, particularly in the treatment of infective endocarditis [11].

The antibacterial action of gentamicin results from its irreversible binding to the 30S ribosomal subunit of susceptible bacteria, leading to inhibition of protein synthesis, production of abnormal proteins, disruption of bacterial membrane integrity, and rapid bacterial cell death. Unlike bacteriostatic antibiotics, gentamicin exhibits concentration-dependent bactericidal activity and possesses a significant post-antibiotic effect, allowing continued suppression of bacterial growth even after plasma drug concentrations decline. These pharmacodynamic characteristics make gentamicin particularly effective in the treatment of severe and rapidly progressing infections [12].

Clinically, gentamicin is widely prescribed for septicemia, neonatal sepsis, complicated urinary tract infections, pyelonephritis, intra-abdominal infections, hospital-acquired pneumonia, postoperative infections, burns, osteomyelitis, pelvic inflammatory disease, and febrile neutropenia. It also serves as an important therapeutic option in resource-limited healthcare settings because of its relatively low cost and broad antimicrobial spectrum. During outbreaks involving multidrug-resistant Gram-negative bacteria, gentamicin frequently remains one of the few effective treatment options available, emphasizing its continuing clinical importance despite the availability of newer antimicrobial agents [13].

Fig 2: Gentamicin Chemical Structure

Despite its therapeutic effectiveness, gentamicin possesses a relatively narrow therapeutic index. Small increases in systemic exposure may substantially elevate the risk of nephrotoxicity and ototoxicity, requiring careful dosage adjustment based on renal function, body weight, age, and serum drug concentration monitoring. Approximately 90% of administered gentamicin is eliminated unchanged through glomerular filtration, making renal function a major determinant of drug clearance. Impaired renal function can further increase drug accumulation, creating a vicious cycle that exacerbates nephrotoxicity [14].

The kidney is the principal target organ for gentamicin toxicity because proximal tubular epithelial cells actively internalize the drug through receptor-mediated endocytosis involving megalin and cubilin receptors. Following intracellular accumulation, gentamicin disrupts lysosomal membranes, impairs mitochondrial function, increases reactive oxygen species production, activates inflammatory signaling pathways, induces apoptosis, and causes tubular necrosis. These pathological events collectively contribute to reduced glomerular filtration rate and impaired renal function [15].

1. 3.  Limitations of Current Preventive Strategies

Numerous preventive approaches have been proposed to minimize gentamicin-induced nephrotoxicity; however, none has completely eliminated the risk of renal injury in clinical practice. Current management primarily focuses on dose optimization, therapeutic drug monitoring, adequate hydration, avoidance of concurrent nephrotoxic medications, and regular assessment of renal function throughout treatment. Although these measures reduce the incidence of nephrotoxicity, they remain largely preventive rather than protective because they do not directly interfere with the molecular mechanisms responsible for renal injury [16].

Therapeutic drug monitoring has become a cornerstone of gentamicin therapy, enabling clinicians to maintain serum concentrations within the therapeutic range while minimizing toxic exposure. Nevertheless, considerable interindividual variability in drug pharmacokinetics often complicates dose adjustment, particularly among critically ill patients, neonates, elderly individuals, and patients with fluctuating renal function. Furthermore, serum drug concentrations do not always accurately reflect intracellular accumulation within renal tubular epithelial cells, where toxicity primarily develops [17].

Adequate hydration is another widely recommended preventive measure because it improves renal perfusion and facilitates urinary excretion of nephrotoxic compounds. However, hydration alone cannot prevent intracellular gentamicin uptake or inhibit oxidative stress, inflammatory activation, or apoptosis. Similarly, reducing treatment duration may decrease cumulative toxicity but is not always clinically feasible when prolonged antimicrobial therapy is required to eradicate severe infections [18].

Several synthetic pharmacological agents possessing antioxidant or anti-inflammatory properties have demonstrated nephroprotective effects in experimental studies. However, many have failed to achieve widespread clinical application because of limited efficacy, potential adverse effects, pharmacokinetic interactions, inconsistent experimental findings, or insufficient clinical evidence. Consequently, there remains no universally accepted pharmacological agent specifically approved for preventing gentamicin-induced nephrotoxicity [19].

Another major limitation involves the relatively late detection of renal injury. Conventional biomarkers such as serum creatinine and blood urea nitrogen often increase only after substantial nephron damage has already occurred. Although novel biomarkers including kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and urinary N-acetyl-β-D-glucosaminidase have shown promise for early detection, their routine clinical use remains limited by issues related to cost, availability, and standardization [20].

1. 4.  Role of Herbal Medicines in Renal Protection

Medicinal plants have served as valuable therapeutic resources for centuries and continue to contribute significantly to contemporary drug discovery and healthcare. According to the World Health Organization, a substantial proportion of the global population relies on traditional herbal medicine as a primary or complementary form of healthcare. The renewed interest in plant-derived therapeutics reflects increasing recognition of their diverse pharmacological activities, relatively favorable safety profiles, and abundance of bioactive phytochemicals capable of modulating multiple disease pathways simultaneously [21].

The nephroprotective potential of herbal medicines has become an area of intensive scientific investigation because renal injury involves complex interactions among oxidative stress, inflammation, mitochondrial dysfunction, apoptosis, autophagy, fibrosis, and vascular alterations. Unlike many synthetic agents that target a single molecular pathway, herbal extracts frequently contain multiple bioactive compounds capable of exerting synergistic therapeutic effects across several pathogenic mechanisms. This multitarget approach may provide greater protection against complex disorders such as drug-induced nephrotoxicity [22].

A wide variety of medicinal plants have demonstrated nephroprotective activity against gentamicin-induced renal injury in experimental studies. Numerous investigations have reported beneficial effects for plants belonging to diverse botanical families, including Curcuma longa, Moringa oleifera, Camellia sinensis, Withania somnifera, Nigella sativa, Phyllanthus niruri, Tinospora cordifolia, Boerhaavia diffusa, Punica granatum, Terminalia chebula, and many others. Their protective effects have been attributed primarily to abundant phytochemicals such as flavonoids, phenolic acids, tannins, lignans, alkaloids, terpenoids, saponins, carotenoids, and essential oils [23].

These phytoconstituents exhibit remarkable antioxidant activity by neutralizing reactive oxygen species, enhancing endogenous antioxidant enzymes including superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase, and reducing lipid peroxidation. Simultaneously, many herbal compounds suppress inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1β, interleukin-6, cyclooxygenase-2, inducible nitric oxide synthase, and nuclear factor-kappa B. Several medicinal plants additionally preserve mitochondrial membrane potential, regulate apoptotic proteins including Bax and Bcl-2, inhibit caspase activation, stimulate autophagic repair mechanisms, and activate cytoprotective pathways such as nuclear factor erythroid 2-related factor 2 (Nrf2) [24].

7. CHALLENGES, CLINICAL TRANSLATION AND FUTURE PERSPECTIVES

Despite the substantial body of experimental evidence supporting the nephroprotective potential of herbal medicines against gentamicin-induced nephrotoxicity, their translation into routine clinical practice remains limited. Numerous medicinal plants and isolated phytochemicals have demonstrated promising antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective effects in preclinical studies. However, several scientific, technical, regulatory, and clinical challenges continue to hinder their successful development as standardized therapeutic agents. These challenges include variability in herbal preparations, lack of standardized extraction protocols, insufficient toxicological evaluation, inadequate pharmacokinetic data, limited clinical evidence, and concerns regarding herb–drug interactions. Addressing these limitations through multidisciplinary research and well-designed translational studies is essential to bridge the gap between laboratory findings and clinical application [86].

1. 1.  Limitations of Preclinical Studies

Most evidence supporting the nephroprotective efficacy of herbal medicines is derived from in vivo animal models, particularly Wistar and Sprague–Dawley rats, with relatively few investigations employing advanced in vitro or translational models. Although these experimental systems provide valuable insights into the mechanisms of gentamicin-induced renal injury, they cannot fully replicate the complexity of human kidney physiology, disease progression, or interindividual variability. Differences in metabolic rate, immune responses, drug metabolism, and renal function between animals and humans may significantly influence treatment outcomes and limit direct clinical extrapolation [87].

Another important limitation is the lack of methodological uniformity among published studies. Considerable variation exists in gentamicin dosage, duration of treatment, animal species, routes of administration, herbal extract preparation, treatment schedules, and outcome assessment. Such heterogeneity makes comparison across studies difficult and complicates the identification of the most effective nephroprotective agents. In addition, many studies employ relatively small sample sizes, evaluate only short-term therapeutic effects, and focus primarily on conventional biochemical markers without investigating long-term renal recovery or molecular mechanisms in sufficient detail [88].

1. 2.  Standardization of Herbal Extracts

Standardization remains one of the greatest challenges in herbal medicine research. The therapeutic efficacy of medicinal plants is influenced by numerous factors, including plant species, geographical origin, climatic conditions, cultivation practices, harvesting season, plant part used, extraction solvent, processing methods, and storage conditions. These variables can lead to significant differences in phytochemical composition and biological activity, even among preparations derived from the same plant species [89].

Furthermore, many experimental studies fail to quantify the concentrations of major bioactive constituents responsible for nephroprotective activity. Without proper phytochemical characterization and quality control, reproducibility becomes difficult and comparison among different investigations remains limited. Future research should emphasize standardized extraction procedures, chemical fingerprinting, identification of bioactive markers, and implementation of Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP) to ensure consistency, quality, and reproducibility of herbal formulations [90].

1. 3.  Safety and Herb-Drug Interactions

Although herbal medicines are generally regarded as safer than synthetic drugs, this perception does not guarantee their complete safety. Natural products may produce adverse effects, exhibit organ toxicity at high doses, or interact with concurrently administered medications. Since gentamicin is commonly prescribed in hospitalized patients receiving multiple therapeutic agents, the possibility of herb–drug interactions should be carefully considered before recommending herbal nephroprotective therapies [91].

Many phytochemicals influence drug-metabolizing enzymes, membrane transport proteins, and renal excretory mechanisms, potentially altering the pharmacokinetics and pharmacodynamics of gentamicin or other co-administered drugs. Unfortunately, comprehensive toxicological evaluations, pharmacokinetic studies, and interaction studies remain limited for many medicinal plants. Long-term safety data are also lacking. Therefore, systematic assessment of toxicity, dose optimization, therapeutic windows, and interaction profiles is necessary before widespread clinical application can be recommended [92].

1. 4.  Nanotechnology and Novel Herbal Drug Delivery Systems

Recent advances in nanotechnology have created new opportunities for improving the therapeutic efficacy of herbal medicines. Many plant-derived bioactive compounds exhibit poor aqueous solubility, low bioavailability, rapid metabolism, and limited tissue distribution, thereby reducing their clinical effectiveness despite promising pharmacological activity. Novel drug delivery systems have the potential to overcome these limitations by enhancing drug stability, improving absorption, prolonging circulation time, and enabling targeted delivery to renal tissues [93].

Various nanocarrier systems, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, phytosomes, dendrimers, and polymeric micelles, have shown considerable promise in improving the delivery of herbal phytochemicals. These advanced formulations may increase therapeutic efficacy while reducing systemic toxicity and dosing frequency. Integration of nanotechnology with phytomedicine therefore represents a promising strategy for developing next-generation nephroprotective therapies against gentamicin-induced kidney injury [94].

1. 5.  Clinical Trials and Translational Research

Despite encouraging preclinical findings, clinical evidence supporting the nephroprotective efficacy of herbal medicines remains scarce. Most medicinal plants have not progressed beyond laboratory investigations, and only a limited number have been evaluated in well-designed randomized controlled clinical trials. Consequently, the safety, efficacy, optimal dosage, treatment duration, and long-term therapeutic benefits of many herbal interventions remain uncertain in human populations [95].

Future translational research should prioritize multicenter clinical trials involving standardized herbal formulations with clearly defined phytochemical profiles. Studies should include pharmacokinetic and pharmacodynamic evaluations, assessment of renal biomarkers, quality-of-life measures, and long-term follow-up to establish clinical effectiveness and safety. Collaboration among pharmacologists, nephrologists, toxicologists, pharmaceutical scientists, clinicians, and regulatory agencies will be essential for accelerating the translation of promising experimental findings into evidence-based therapeutic applications [96].

1. 6.  Future Research Priorities

Future investigations should focus on developing standardized, scientifically validated herbal nephroprotective agents with clearly established mechanisms of action and favorable safety profiles. Advanced molecular techniques, including transcriptomics, proteomics, metabolomics, systems biology, and network pharmacology, should be employed to better understand the complex interactions between phytochemicals and renal signaling pathways. Artificial intelligence and computational drug discovery approaches may further facilitate the identification of novel phytoconstituents with enhanced nephroprotective potential [97].

Greater emphasis should also be placed on isolation of active compounds, pharmacokinetic characterization, toxicity assessment, dose optimization, and formulation development. Emerging technologies such as nanomedicine, targeted drug delivery systems, and combination therapies involving phytochemicals and conventional drugs offer promising avenues for improving therapeutic outcomes. In addition, harmonization of experimental protocols, establishment of internationally accepted quality standards, and increased investment in translational and clinical research will be essential for transforming herbal nephroprotective agents from promising experimental therapies into safe, effective, and clinically accepted interventions for the prevention and management of gentamicin-induced nephrotoxicity [98].

CONCLUSION

Gentamicin remains one of the most effective and widely prescribed aminoglycoside antibiotics for the treatment of severe bacterial infections; however, its clinical utility continues to be limited by its well-documented nephrotoxic effects. The development of gentamicin-induced nephrotoxicity is a multifactorial process involving oxidative stress, excessive generation of reactive oxygen species, inflammatory activation, mitochondrial dysfunction, apoptosis, endoplasmic reticulum stress, and progressive fibrotic remodeling. These interconnected molecular events primarily affect the proximal tubular epithelial cells, leading to impaired renal function and, in severe cases, acute kidney injury. A comprehensive understanding of these pathogenic mechanisms has facilitated the identification of several therapeutic targets for preventing or minimizing renal damage.

The evidence reviewed in this article demonstrates that herbal medicines possess considerable potential as nephroprotective agents against gentamicin-induced kidney injury. A wide variety of medicinal plants, including Curcuma longa, Nigella sativa, Moringa oleifera, Withania somnifera, Boerhaavia diffusa, Tinospora cordifolia, Phyllanthus niruri, and several others, have consistently shown renoprotective effects in experimental models. These beneficial effects are largely attributed to their rich phytochemical composition, including polyphenols, flavonoids, alkaloids, terpenoids, phenolic acids, tannins, and saponins. Through their multitarget pharmacological actions, these bioactive compounds effectively reduce oxidative stress, suppress inflammatory responses, inhibit apoptosis, preserve mitochondrial integrity, regulate critical signaling pathways such as Nrf2, NF-κB, MAPK, and PI3K/Akt, and promote recovery of renal tissue architecture.

Experimental studies have consistently reported improvements in both biochemical and histopathological parameters following herbal treatment. Restoration of antioxidant enzyme activity, reduction in serum creatinine and blood urea nitrogen levels, suppression of lipid peroxidation, preservation of glomerular and tubular morphology, and attenuation of inflammatory cytokine production collectively support the therapeutic promise of medicinal plants in mitigating gentamicin-induced nephrotoxicity. These findings highlight the advantage of herbal medicines in targeting multiple pathological mechanisms simultaneously, an approach that may offer greater therapeutic benefit than interventions directed toward a single molecular pathway.

Despite these encouraging findings, several important challenges remain before herbal nephroprotective agents can be routinely integrated into clinical practice. The majority of available evidence is derived from preclinical animal studies, while high-quality clinical trials evaluating standardized herbal formulations remain limited. Furthermore, considerable variability in plant sources, extraction methods, phytochemical composition, dosage regimens, and experimental protocols affects reproducibility and limits direct comparison among studies. Additional concerns regarding long-term safety, pharmacokinetics, herb–drug interactions, and regulatory standardization must also be addressed to ensure safe and effective clinical application.

Future research should therefore focus on the development of standardized herbal formulations with well-characterized phytochemical profiles, comprehensive toxicological evaluation, and rigorous quality control. Advances in molecular biology, systems pharmacology, metabolomics, artificial intelligence, and nanotechnology-based drug delivery systems provide exciting opportunities to enhance the bioavailability, efficacy, and targeted delivery of plant-derived nephroprotective compounds. Well-designed multicenter randomized controlled clinical trials, together with translational research integrating mechanistic, pharmacokinetic, and clinical outcomes, will be essential to establish the therapeutic value of these agents in human populations.

Funding and Conflict of Interest Statement: The authors declare that no specific funding was received for this study from any public, commercial, or not-for-profit funding agency. The authors further declare that they have no financial associations, competing interests, employment relationships, consultancy roles, stock ownership, honoraria, or other potential conflicts of interest that could have influenced the work reported in this manuscript. All authors have approved the final version of the manuscript and take full responsibility for its content.

REFERENCES

1. Daoud G, Ahsan F, Mahmood T, Bano S, Ansari VA, Zaidi SM. Plant-based nephroprotective agents: a review of strategies to combat drug-induced kidney damage. Clinical Phytoscience. 2026 Feb 9;12(1):1.
2. Bwambale W, Oka VO, Onaadepo O, Etukudo EM, Owu DU, Nkanu EE, Shehu UU, Bwambale F, Abura AG. Advancing nephroprotective strategies: the role of naringenin in preventing gentamicin-induced nephrotoxicity. Discover Medicine. 2025 Apr 28;2(1):115.
3. Jalali J, Ghasemzadeh Rahbardar M. Rosemary: A promising therapeutic agent in alleviating nephrotoxicity. Journal of Food Biochemistry. 2025;2025(1):5519628.
4. Akter F, Sovon MS, Hossain B, Islam MA, Das S, Biswas A, Uddin MS, Hasan MM. Maesa ramentacea Leaf Extract Protects Against Gentamicin‐Induced Nephrotoxicity in Wistar Rats by Modulating Renal Oxidative Stress, Inflammation and Apoptosis. Veterinary Medicine International. 2026;2026(1):6127118.
5. Abukhalil MH, Al-Alami Z, Altaie HA, Aladaileh SH, Othman SI, Althunibat OY, Alfwuaires MA, Almuqati AF, Alsuwayt B, Rudayni HA, Allam AA. Galangin prevents gentamicin-induced nephrotoxicity by modulating oxidative damage, inflammation and apoptosis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 Apr;398(4):3717-29.
6. Askari H, Zeinali F, Haghi-Aminjan H, Hafizi SM, Alirezaei A. The protective effects of Ocimum basilicum extract against gentamicin-induced nephrotoxicity in male rats; an anti-inflammatory, anti-oxidative and antiapoptotic action. Immunopathologia Persa. 2019 Jun 15;5(2):e21-.
7. Antar SA, Al Karmalawy AA, Mourad AA, Mourad M, Elbadry M, Saber S, Khodir AE. Protective Effects of Mirazid on Gentamicin-induced Nephrotoxicity in Rats through Antioxidant, Anti-inflammatory, JNK1/iNOS, and Apoptotic Pathways, Novel Mechanistic Insights.
8. Ijaz MU, Mustafa S, Hamza A, Almutairi BO, Almutairi MH, Riaz MN. Evaluation of possible protective role of glabridin against gentamicin-instigated nephrotoxicity via attenuation of oxidative stress. Journal of King Saud University-Science. 2023 Jul 1;35(5):102692.
9. Gumbar S, Bhardwaj S, Mehan S, Khan Z, Narula AS, Kalfin R, Tabrez S, Zughaibi TA, Wasi S. Renal mitochondrial restoration by gymnemic acid in gentamicin-mediated experimental nephrotoxicity: evidence from serum, kidney and histopathological alterations. Frontiers in Pharmacology. 2023 Jul 13;14:1218506.
10. Bwambale W, Oka VO, Etukudo EM, Owu DU, Nkanu EE, Okon IA, Emmanuel SD, Shehu UU, Wilber N, Kambere A, Arinaitwe R. Nephroprotective activity of naringenin in gentamicin-induced nephrotoxicity in male Wistar rats: In-vivo and in-silico evaluation. Pharmacological Research-Natural Products. 2025 Oct 14:100406.
11. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food and Chemical Toxicology. 2003 Nov 1;41(11):1447-52.
12. Alkhedaide AQ. Impacts of gentamycin toxicity: nephroprotective role of guarana through different signaling pathways. Toxicology Research. 2024 Oct;13(5):tfae167.
13. Gamaan MA, Zaky HS, Ahmed HI. Gentamicin-induced nephrotoxicity: A mechanistic approach. Azhar International Journal of Pharmaceutical and Medical Sciences. 2023 Jun 1;3(2):11-9.
14. Habib HA, Heeba GH, Abdel‐latif R. Diacerein Ameliorates Gentamicin‐Induced Nephrotoxicity via Regulating PI3k/AKT‐Mediated Nrf‐2 and NF‐κB Pathways: Forge the Mechanistic Insight. Journal of Biochemical and Molecular Toxicology. 2026 Jun;40(6):e70945.
15. Rahman A, Penumallu NR, Abass S, Parveen B, Parveen R, Ahmad S. Drug-induced nephrotoxicity and its reversal using botanicals of traditional Indian medicine in different animal models: way forward. Future Journal of Pharmaceutical Sciences. 2025 Oct 13;11(1):141.
16. Randjelovic P, Veljkovic S, Stojiljkovic N, Sokolovic D, Ilic I. Gentamicin nephrotoxicity in animals: Current knowledge and future perspectives. EXCLI journal. 2017 Mar 24;16:388.
17. Bunel V, Qu F, Duez P, Xu QH. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015 Jul 1;1(3):47-66.
18. Firdous SM, Mahanta S, Malik S. Underpinning the role of natural products against cisplatin-induced nephrotoxicity in rodent models. Medicinal Chemistry Research. 2025 Jul 21:1-20.
19. Butt MS, Randhawa MA, Shahid M. Nephroprotective effects of red beetroot‐based beverages against gentamicin‐induced renal stress. Journal of food biochemistry. 2019 Jul;43(7):e12873.
20. Ali MM, Al-Mokaddem AK, Abdel-Sattar E, El-Shiekh RA, Aljuaydi SH, Shaheed IB. The nephroprotective potential of russelioside B isolated from Caralluma quadrangula in gentamicin-induced acute kidney injury via modulation of SIRT-1 pathway. Scientific Reports. 2025 Dec 13.
21. Zenkić E, Karović V, Šehović N, Mitrašinović-Brulić M, Suljević D. Protective and anti-inflammatory potential of Rhodiola rosea against gentamicin-induced nephrotoxicity: evidence from a study in Wistar rats with emphasis on novel biomarkers. Comparative Clinical Pathology. 2026 Dec;35(1):68.
22. Joshi S, Beniwal R, Gabrani R. Drug‐Induced Nephrotoxicity: Biomarker‐Based Phytotherapeutic Interventions. Journal of Applied Toxicology. 2026 Jul;46(7):2275-92.
23. Goel R, Kumar N, Mishra R, Kumar G, Singh N, Bhardwaj S, Puri D. Potential protective effects of Acacia nilotica (L.) against gentamicin-induced nephrotoxicity by suppressing renal redox imbalance, inflammatory stress and caspase-dependent apoptosis in Wistar rats. Drug and Chemical Toxicology. 2025 Jan 2;48(1):163-71.
24. Aurori M, Andrei S, Dreanca AI, Morohoschi AG, Cotul M, Niculae M, Nan MI, Codea AR, Gal AF. The nephroprotective effect of cornelian cherry (Cornus mas L.) and Rowanberry (Sorbus aucuparia L.) in gentamicin-induced nephrotoxicity on Wistar rats with emphasis on the evaluation of novel renal biomarkers and the antioxidant capacity in correlation with nitro-oxidative stress. Nutrients. 2023 Oct 16;15(20):4392.
25. Tienda-Vázquez MA, Morreeuw ZP, Sosa-Hernández JE, Cardador-Martínez A, Sabath E, Melchor-Martínez EM, Iqbal HM, Parra-Saldívar R. Nephroprotective plants: a review on the use in pre-renal and post-renal diseases. Plants. 2022 Mar 18;11(6):818.
26. Asante J, Moomin A, Ofori M, Jude T, Adu-Gyamfi PK, Yeshuna M, Benneh CK, Ansah C, Mensah KB. Polyherbal renal tea extract shows anti-inflammatory and antioxidant effects against gentamicin-induced nephrotoxicity in guinea pigs. Egyptian Journal of Basic and Applied Sciences. 2025 Dec 31;12(1):1-5.
27. Zhou Y, Li S, Shao M, Qian Y, Lan T, Yao D, Zhan T, Li T, Shao Z, Ye C, Zhuang S. Exploring Chinese herbal medicines for acute kidney injury: pharmacological mechanisms and clinical potential. Drug Design, Development and Therapy. 2026 Dec 31:555264.
28. Imam ST, Imam SS. The Cream which relieves the pain of Menstrual cramps without interfering with the Hormones or Period Cycle. Research Journal of Pharmacy and Technology. 2023; 16(3):1239-6.
29. Imam SS. Topical Formulation Constituted with Transferosomes for the Treatment Of Non-Melanoma Skin Cancer. Asian J Pharm Clin Res. 2023 May 7;16(5):27-32.
30. IMAM SS. NANOPARTICLES: THE FUTURE OF DRUG DELIVERY. Int J Curr Pharm Sci. 2023 Nov. 15;15(6):8-15.
31. Imam SS, Mehdi S, Mansuri A. A COMPREHENSIVE REVIEW ON THE PHARMACOLOGICAL POTENTIAL OF RED GINSENG OIL, TEA TREE OIL AND HEMP SEED OIL. European Journal of Biomedical. 2024;11(4):167-77.
32. Imam SS. Sublingual Tablets Amalgamated with Nano-particles and natural products to treat Oral Cancer. 2024; 17(5): 2056-62.
33. Imam SS, Mehdi S. Factors Affecting Pharmaceutical Pricing In India. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES. 2024;2(4):1367-1384. DOI: 10.5281/zenodo.11314004.
34. Mehdi S, Tabrez UZ, Imam SS. Management of Green Pharmaceuticals. International Journal of Pharmaceutical Sciences And Research. 2024;15(7):1951-1962. DOI: 10.13040/IJPSR.0975-8232.15(7).1951-62.
35. Imam SS. EVALUATING THE IMPACT OF US TARIFFS AND EVOLVING GLOBAL TRADE POLICIES ON PHARMACEUTICAL PRICING, MARKET PENETRATION, AND THE SUPPLY OF GENERIC MEDICINES FROM INDIA TO THE WORLD. Journal of Pharmacoeconomics and Pharmaceutical Management. 2025 Nov 7;11(2):27-34.

36. Sujana D, Saptarini NM, Sumiwi SA, Levita J. Nephroprotective activity of medicinal plants: A review on in silico-, in vitro-, and in vivo-based studies. Journal of Applied Pharmaceutical Science. 2021 Oct 3;11(10):113-27.
37. Ungur RA, Borda IM, Codea RA, Ciortea VM, Năsui BA, Muste S, Sarpataky O, Filip M, Irsay L, Crăciun EC, Căinap S. A flavonoid-rich extract of Sambucus nigra L. reduced lipid peroxidation in a rat experimental model of gentamicin nephrotoxicity. Materials. 2022 Jan 20;15(3):772.
38. Yuan M, Briscese K, Hong TS, Brunetti L. Natural products for the prevention of antibiotic-associated kidney injury. Current opinion in toxicology. 2022 Dec 1;32:100363.
39. Li J, Li T, Li Z, Song Z, Gong X. Potential therapeutic effects of Chinese meteria medica in mitigating drug-induced acute kidney injury. Frontiers in Pharmacology. 2023 Apr 3;14:1153297.
40. Hassanein EH, Ali FE, Kozman MR, Abd El-Ghafar OA. Umbelliferone attenuates gentamicin-induced renal toxicity by suppression of TLR-4/NF-κB-p65/NLRP-3 and JAK1/STAT-3 signaling pathways. Environmental Science and Pollution Research. 2021 Mar;28(9):11558-71.
41. Ahamad R, Mubin N, Alnukhali M, Akhtar M, Aqil M, Mujeeb M, Ahmad A. Oxidative Stress-Driven Mechanisms and Biomarkers of Drug-Induced Nephrotoxicity: Translational Insights and Therapeutic Implications. Antioxidants. 2026 Mar 25;15(4):412.
42. Govindappa PK, Gautam V, Tripathi SM, Sahni YP, Raghavendra HL. Effect of Withania somnifera on gentamicin induced renal lesions in rats. Revista Brasileira de Farmacognosia. 2019 Mar 1;29(2):234-40.
43. Fadlalla EA, Seddik A. Anti-inflammatory and nephroprotective influence of virgin coconut oil on gentamicin-induced nephrotoxicity in nondiabetic and streptozotocin-induced diabetic rats. African Journal of Food, Agriculture, Nutrition and Development. 2023 Apr 2;23(2):22492-512.
44. Albalawi RS, Binmahfouz LS, Hareeri RH, Shaik RA, Bagher AM. Parthenolide phytosomes attenuated gentamicin-induced nephrotoxicity in rats via activation of Sirt-1, Nrf2, OH-1, and NQO1 axis. Molecules. 2023 Mar 17;28(6):2741.
45. Zishan SA, Uddin MI, Naima J, Ibban S. Conventional medicines used for kidney protection in Bangladesh: a review. Infectious Diseases and Herbal Medicine. 2023 Sep 12;4.
46. Elhassaneen YA, Al-Sherif FA, Ragab SS, Khafagi MM, Hashem BM. Potential Preventive and Treatment Effects of Arak (Salvadora Persica) Against Gentamicin-induced Kidney Disorders in Male Albino Rats. American Journal of Medical Sciences. 2024;12(2):27-40.
47. Imam SS. The future of non-invasive ways to treat cancer. Int J Pharm Sci & Res. 2021; 12(8): 4684-96.
48. Imam SS, Agarwal S. A Pragmatic Approach To Treat Lung Cancer Through Loading Theaflavin -3,3’-Digallate And Epigallocatechin Gallate In Spanlastic. Asian J Pharm Clin Res. 2021 Nov 7; 14(11): 1-8.
49. Imam SS, Imam ST, Mdwasifathar, Kumar R, Ammar MY. Interaction Between Ace 2 And Sars-Cov2, And Use Of EGCG And Theaflavin To Treat Covid 19 In Initial Phases. International Journal of Current Pharmaceutical Research. 2022 Mar; 14(2):5- 10.
50. Imam SS, Sharma R. Natural compounds promising way to treat Lung Cancer. International Journal of Pharmaceutical Research and Applications. 2023; 8(2): 552- 558.
51. Imam SS, Sharma S, Kumari D, Khan S, Pathak P, Katiyar D. An Expedient Approach to Treat Asthma through Non-Steroidal, Natural Transferosomes Aerosol System. Innovare journal of medical sciences. 2022; 10(6): 7-11.
52. Imam SS, Imam ST, Agarwal S, Kumar R, Ammar MY, Athar MW, Akthar A. Lung Cancer Therapy Using Naturally Occurring Products and Nanotechnology. Innovare journal of medical sciences. 2022; 10(4): 1-5.
53. Imam SS. Pharmaceutical Marketing Management in India. Journal of Pharmacoeconomics and Pharmaceutical Management. 2024 Oct 23;10(2):37-48.
54. Yazdanpanah Z, Sirjani A, Moradi EV, Kakhki BR, Jalali J, Rahbardar MG. Pomegranate (Punica granatum L.): A narrative review of its protective role against nephrotoxicity. Fitoterapia. 2025 Aug 18:106827.
55. Dhavane SS, Laware RB. Kaempferol-rich Thespesia lampas leaf extract mitigates gentamicin-induced nephrotoxicity via antioxidant and anti-inflammatory mechanisms in wistar rats. Journal of Applied Pharmaceutical Research. 2026 May 15;14(3):253-70.
56. Arya M, Bansal P, Pentela B, Mazumder A. A review on herbal therapeutics in nephroprotection: exploring herbal agents, bioactive compounds, formulations, mechanisms of action, and comparison with conventional treatments.
57. Akinaw MA, P Nair SK, Usure RE, Leta B, Kedir A, Mamo SA, Waritu NC, Jemal M, Mulat BK. Nephroprotective Effect of the Leaf Extract of Ajuga remota Benth Against Gentamicin-Induced Nephrotoxicity in Swiss Albino Mice. Journal of Experimental Pharmacology. 2024 Dec 31:159-71.
58. Nishat RJ. Oxidative Stress and Antioxidant Response in Gentamicin-Treated Rats–Role of Green Tea Extract on Renal Malondialdehyde (MDA) Levels. The Planet. 2025;9(01):201-6.
59. Chen L, Deng Y, Hu J, Gong X. Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury. Frontiers in Pharmacology. 2025 Feb 19;16:1539886.
60. Alyami SA, Alnaim RS, Alaraifi RK, Alnaim DM, Alnaim KS, Alnaim WA, Albekery MA, Mohamed ME, Younis NS. Alpinia galanga Essential Oil Mitigates Gentamicin-Induced Renal Injury: In silico and in vivo Studies. Kidney Diseases. 2025 Jan 1;11(1):722-46.
61. Wati DP, Ilyas SY. Renoprotective potential of flavonoids-rich against doxorubicin-induced in animal models: A review. Int J App Pharm. 2024;16(6):28-37.
62. Akila AA, Gad RA, Ewees MG, Abdul-Hamid M, Abdel-Reheim ES. Clopidogrel protects against gentamicin-induced nephrotoxicity through targeting oxidative stress, apoptosis, and coagulation pathways. Naunyn-schmiedeberg's Archives of Pharmacology. 2025 Mar;398(3):2609-25.
63. Josiah SS, Crown OO, Akinmoladun AC, Olaleye MT. Renoprotective property of the flavonoid-rich extract of Kigelia africana fruits on gentamicin-induced nephrotoxicity in rats. Comparative Clinical Pathology. 2020 Aug;29(4):815-28.
64. Karimian A, Mahmoudi L. Silymarin’s potential in countering drug-induced cardiotoxicity, nephrotoxicity, and hepatotoxicity: a narrative review. Trends in Pharmaceutical Sciences and Technologies. 2024 Mar 1;10(1):15-24.
65. Yıldırım M, Erşatır M, Değirmenci U, Yigin A, Unal MB, Guldur ME, Demirkol O, Giray ES. Potential Protective Effects of Ruta Chalepensis L. Extracts Against Gentamicin-Induced Nephrotoxicity via Reduction on Apoptotic, DNA Damage and Oxidative Stress Markers in Mice. International Journal of Environmental Health Research. 2023 Dec 2;33(12):1533-45.
66. Chen X, Wu Z. Ameliorative effect of biochanin A against gentamicin-induced nephrotoxicity in rats. Pharmacognosy Magazine. 2025 Dec;21(4):1418-26.
67. Abdelrahaman D, Shanab O, Abdeen A, Abdelkader A, Elazab KM, Kouriem H, Maher ZM, Abu-Almakarem AS, Mohamed ME, Elbastawisy YM, Elsehrawy MG. Bee venom ameliorates gentamicin-induced kidney injury by restoring renal aquaporins and enhancing antioxidant and anti-inflammatory activities in rats. Frontiers in pharmacology. 2025 Apr 17;16:1525529.
68. Mathew S, Rao RR, Shenoy PJ, Poojar B, Rao GM, Teerthanath S. Nephroprotective potential of sinigrin against gentamicin induced kidney damage in Wistar rats: a preclinical evaluation.
69. Djoko SK, Nchouwet ML, Kamani SL, Kodjio N, Kamanyi A, Ngnokam SL. Extracts from commelina diffusa protect against gentamicin-induced nephrotoxicity in wistar rats. Saudi Journal of Biomedical Research. 2020;5:61-8.
70. Moeini R, Memariani Z, Enayati A, Gorji N, Kolangi F. Nephrotonic and nephroprotective medicinal herbs in traditional persian medicine: Review and assessment of scientific evidence. Current Traditional Medicine. 2022 Jun 1;8(3):11-25.
71. VYAS J, MAHESHWARI V, KUMAR SK, JOSEPH LD. Effect of Tinospora cordifolia on Oxidative Stress Level Due to Drug Induced Nephrotoxicity: An Experimental Study. Journal of Clinical & Diagnostic Research. 2022 Oct 1;16(10).
72. AlRamadneh TN, Abdulsahib WK, Ismael SH, Roopashree R, Mohanty B, Nandhini SU, Arora V, Chauhan AS, Farhood B. Renoprotective properties of resveratrol in the treatment of renal fibrosis, renal cell carcinoma, diabetic nephropathy and nephrotoxicity: a review of current evidence based on underlying cellular mechanisms. Toxicology Mechanisms and Methods. 2026 Mar 24;36(3):354-75.
73. Jafari A, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature. Expert opinion on drug safety. 2013 Jul 1;12(4):523-43.
74. Georgiev T, Nikolova G, Dyakova V, Zlateva S, Karamalakova Y, Georgieva E, Petkova-Parlapanska K, Ananiev J, Dobreva A, Hadzhibozheva P. Antioxidant potential and oxidative stress modulation of Geranium macrorrhizum L. oil extract in gentamicin-induced nephrotoxicity. Pharmaceuticals. 2025 Aug 27;18(9):1283.
75. Balakumar P, Alshahrani S, Khan NA, Varatharajan R, Sundram KM. Differential Pre‐and Post‐Treatment Effects of Low‐Dose Antidyslipidemic Drugs on Gentamicin‐Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study. Journal of Applied Toxicology. 2026 Jun;46(6):1879-96.
76. Matar MS, Ali LH. Therapeutic and preventive effects of pumpkin seed extract on gentamicin-induced nephrotoxicity in rats. Babcock University Medical Journal. 2025 Dec 31;8(2):156-67.
77. Dawane JS, Dhande P, Shukla CD, Dhakne A. Evaluation of potential of Revstone® on gentamicin-induced renal toxicity in Wistar rats: a comparative study of the capsule and syrup forms. Frontiers in Pharmacology. 2026 Mar 3;17:1765648.
78. Jawindra MR, Yuniarti WM, Kurniawati DK, Yulinda IV, Safiranisa A, Fachrudin AN, Sektiari Lukiswanto B, Widyawati R. Therapeutic Potential Of Hibiscus Sabdariffa In Minimizing Gentamicin-Induced Nephrotoxicity And Testicular Histopathological Alterations In Rats. Archives of Razi Institute. 2025 Dec 21.
79. Shamna JJ, Jose J, Shijikumar A, Ahmed AR. A brief study of nephrotoxicity and nephroprotective agents. Indian J. Pharm. Biol. Res. 2020;8(1):9-13.
80. Meraati Z, Ale-Ebrahim M, Mortazavi P, Chitgar A, Aghebat_Bekheir S. Investigation of Protective Effect of Hydroalcoholic Extract of Walnut Tree Leaves (Juglans regia) on Gentamicin-Induced Nephrotoxicity in Male Wistar Rats. Natural Product Communications. 2025 Jan;20(1):1934578X251314344.
81. Saifi A, Rastogi P, Mujahid M, Hussain MS. Plant natural products: A lead for nephroprotection. Journal of Drug Delivery & Therapeutics. 2024 Sep 1;14(9).
82. Ahmed HE, Abdlrahman S, Ahmed Mohamed S, Bilal T, Elghazali FE, Elbadwi SM. Nephroprotective effect of Acacia senegal (Gum Arabic) against gentamicin induced nephrotoxicity in rats. Int. J. Res.-Granthaalayah. 2022;10:120-8.
83. Sahu V, Panjwani D, Mishra V. A review of nephrotoxins and their mechanism of nephrotoxicity. Current Functional Foods. 2024 Sep;2(2):E260124226378.
84. Ewees MG, Abdelzaher LA, El-Shoura EA, Rahman FE, Shabaan AM, Embaby MA, Abdelmenem AM, Ahmed YM. β-Sitosterol attenuates gentamicin-induced nephrotoxicity via ADAM-17/ACE2/Ang 1–7/MasR Axis modulation in rats. International Immunopharmacology. 2026 Mar 15;173:116267.
85. Prasanth D, Reddy LS, Dasari T, Bhavanam PR, Ahmad SF, Nalluri R, Pasala PK. LC/MS-based profiling of Hedyotis aspera whole-plant methanolic extract and evaluation of its nephroprotective potential against gentamicin-induced nephrotoxicity in rats supported by in silico studies. Separations. 2023 Oct 30;10(11):552.
86. Abouelhamd A, Shehata NE, Abdel-Hafez SM, Abu-Baih DH. Vincamine induces cytoprotective autophagy via regulation of ampk/mtor signaling pathway in gentamicin-induced hepatotoxicity and nephrotoxicity in rats. Scientific Reports. 2025 Jun 20;15(1):20202.
87. Kumar M, Dhar H, Salwan P, Yadav DK, Mondal A, Singh K. Pharmacodynamic interaction of ethyl acetate fraction from alcoholic extract of Phyllanthus niruri leaves with gentamicin-induced nephrotoxicity in Wister albino rats. Indian Journal of Physiology and Pharmacology. 2026 Jun 3.
88. Moraes Carlesso R, Cappellari YL, Boeff DD, da Costa Pereira A, Schmitt Rusch E, de Souza Claudino T, Ritter MR, Konrath EL. Nephroprotective Plant Species Used in Brazilian Traditional Medicine for Renal Diseases: Ethnomedical, Pharmacological, and Chemical Insights. Plants. 2025 Feb 20;14(5):648.
89. Gaurav, Sharma I, Khan MU, Zahiruddin S, Basist P, Ahmad S. Multi-mechanistic and therapeutic exploration of nephroprotective effect of traditional ayurvedic polyherbal formulation using in silico, in vitro and in vivo approaches. Biomedicines. 2023 Jan 9;11(1):168.
90. Georgiev T, Nikolova G, Dyakova V, Karamalakova Y, Georgieva E, Ananiev J, Ivanov V, Hadzhibozheva P. Vitamin E and silymarin reduce oxidative tissue damage during gentamycin-induced nephrotoxicity. Pharmaceuticals. 2023 Sep 27;16(10):1365.
91. Siangjong L, Meetam P. Protective effect of pinostrobin against gentamicin-induced toxicity in human renal proximal tubular cells. Pharmacia. 2024 Aug 2;71:1-7.
92. Garg M, Arora A, Saini S, Kumari S, Deswal G, Grewal AS. Medicinal Plant-derived Phytochemicals in the Prevention and Management of Chronic Kidney Disease. Current Pharmaceutical Biotechnology. 2026.
93. Javed A, Mahmood T, Tiwari R, Ahsan F, Ansari VA, Bano S, Khan MM, Khan A. Navigating nephropathy and nephrotoxicity: understanding pathophysiology unveiling clinical manifestations, and exploring treatment approaches. Journal of Basic and Clinical Physiology and Pharmacology. 2025 Mar 1;36(2-3):69-93.
94. Korkut Celikates B, Ilgin S, Yilmaz MU, Atli Eklioglu O. Targeting the powerhouse: the mitochondrial perspective on gentamicin-induced kidney injury. Archives of Toxicology. 2026 Feb 7:1-3.
95. Mahamud AS, Tanvir IA, Kabir E, Ahmed K, Hosen MM, Uddin J. Insights into nephroprotective potentials of luteolin and pharmacological advances: a review. Journal of Biologically Active Products from Nature. 2024 May 3;14(3):251-85.
96. Petkova-Parlapanska K, Stefanov I, Ananiev J, Georgiev T, Hadzhibozheva P, Petrova-Tacheva V, Kaloyanov N, Georgieva E, Nikolova G, Karamalakova Y. Sambucus nigra-Lyophilized Fruit Extract Attenuated Acute Redox–Homeostatic Imbalance via Mutagenic and Oxidative Stress Modulation in Mice Model on Gentamicin-Induced Nephrotoxicity. Pharmaceuticals. 2025 Jan 13;18(1):85.
97. Zhao Q, Jin M, Zhao Q, Wang Z, Zhao C, Xue X, Qiao X, Qu P, Han D, Tao R. Natural products in traditional Chinese medicine for renal fibrosis: a comprehensive review. Frontiers in Pharmacology. 2025 Apr 16;16:1560567.
98. Georgiev T, Nikolova G, Dyakova V, Karamalakova Y, Georgieva E, Ananiev J, Ivanov V, Hadzhibozheva P. Vitamin E and Silymarin Reduce Oxidative Tissue Damage during Gentamycin-Induced Nephrotoxicity. Pharmaceuticals. 2023;16:1365.